Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention.
Methods: The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020-March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein-1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated.
Results: One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04-0.90; P = .04). Conversely, patients with IP-10 <2500 pg/mL did not show these differences.
Conclusions: IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 4 vom: 10. Apr., Seite ofad133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trigo-Rodríguez, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 11.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad133 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355401169 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355401169 | ||
| 003 | DE-627 | ||
| 005 | 20231226064251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad133 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355401169 | ||
| 035 | |a (NLM)37035487 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trigo-Rodríguez, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention | ||
| 520 | |a Methods: The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020-March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein-1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated | ||
| 520 | |a Results: One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04-0.90; P = .04). Conversely, patients with IP-10 <2500 pg/mL did not show these differences | ||
| 520 | |a Conclusions: IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a IP-10 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a sarilumab | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Cárcel, Sheila |e verfasserin |4 aut | |
| 700 | 1 | |a Navas, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Espíndola-Gómez, Reinaldo |e verfasserin |4 aut | |
| 700 | 1 | |a Garrido-Gracia, José Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban Moreno, María Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a León-López, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Crespo, Pedro María Martínez |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Eduardo Aguilar |e verfasserin |4 aut | |
| 700 | 1 | |a Vinuesa, David |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Palacios, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Camacho, Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Gutiérrez, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Marcos, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Roldán, Concepción |e verfasserin |4 aut | |
| 700 | 1 | |a León, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Caño, Alexandra Aceituno |e verfasserin |4 aut | |
| 700 | 1 | |a Corzo-Delgado, Juan E |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Nadales, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Riazzo, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a de la Fuente, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Jurado, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Torre-Cisneros, Julián |e verfasserin |4 aut | |
| 700 | 1 | |a Merchante, Nicolás |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 4 vom: 10. Apr., Seite ofad133 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:4 |g day:10 |g month:04 |g pages:ofad133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad133 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 4 |b 10 |c 04 |h ofad133 | ||